Featured Research

from universities, journals, and other organizations

Study Suggests Antipsychotics Do Not Raise Risk Of Stroke In Alzheimer's Patients

Date:
July 28, 2004
Source:
University Of Southern California
Summary:
Antipsychotic drugs do not seem to increase the risk of stroke or other adverse cerebrovascular events in agitated or psychotic people with Alzheimer's Disease, according to research presented at the 9th International Conference on Alzheimer's Disease and Related Disorders.

LOS ANGELES, July 22, 2004 – Antipsychotic drugs do not seem to increase the risk of stroke or other adverse cerebrovascular events in agitated or psychotic people with Alzheimer's Disease, according to research presented today in a "Hot Topics" symposium at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD) in Philadelphia, sponsored by the Alzheimer's Association.

Related Articles


Agitation is a common symptom in the more progressive stages of Alzheimer's disease, sometimes even advancing into full-blown psychosis--hallucinations, delusions, and more. Physicians have been prescribing antipsychotic medications to treat these symptoms for some time, but not all of them have been tested specifically on people with degenerative brain diseases like Alzheimer's.

Lon Schneider, M.D., professor of psychiatry and neurology at the Keck School of Medicine of USC and a professor of gerontology at USC's Leonard Davis School of Gerontology, today presented data pooled from two recent studies of a fairly new atypical antipsychotic drug, quetiapine (brand name Seroquel, produced by AstraZeneca), to determine whether the drug increases risk of stroke or transient ischemic attack in people with Alzheimer's.

Schneider and his colleagues from the University of Rochester Medical Center, the Medical University of South Carolina and AstraZeneca looked at data from the two studies, which together followed 684 institutionalized patients with dementia, 86 percent of whom had Alzheimer's disease. The patients had an average age of 83 years, and were taking either quetiapine, haloperidol (Haldol, an older antipsychotic medication) or a placebo.

Very few of the patients on any of these regimens had a "cerebrovascular adverse event." In fact, just one of the 355 patients on quetiapine experienced such an event, as did just one of the 116 patients on haloperidol and four of the patients taking placebo. This translated to an incidence rate of 0.3 percent for quetiapine, 0.9 percent for haloperidol and 1.9 percent for placebo.

"Although the studies were not designed with the primary purpose of evaluating the incidence of these side effects and the sample sizes were small," Schneider said, "the data available so far are compatible with no increased risk for cerebrovascular adverse events with quetiapine in this population."

###

Lon Schneider, Pierre Tariot, Jacobo Mintzer, Margaret C. Minkwitz, Kate Zhong, "Cerebrovascular adverse events with quetiapine: a pooled analysis in elderly patients with dementia." 9th International Conference on Alzheimer's Disease and Related Disorders, Thursday, July 22, 2004.


Story Source:

The above story is based on materials provided by University Of Southern California. Note: Materials may be edited for content and length.


Cite This Page:

University Of Southern California. "Study Suggests Antipsychotics Do Not Raise Risk Of Stroke In Alzheimer's Patients." ScienceDaily. ScienceDaily, 28 July 2004. <www.sciencedaily.com/releases/2004/07/040726090342.htm>.
University Of Southern California. (2004, July 28). Study Suggests Antipsychotics Do Not Raise Risk Of Stroke In Alzheimer's Patients. ScienceDaily. Retrieved March 29, 2015 from www.sciencedaily.com/releases/2004/07/040726090342.htm
University Of Southern California. "Study Suggests Antipsychotics Do Not Raise Risk Of Stroke In Alzheimer's Patients." ScienceDaily. www.sciencedaily.com/releases/2004/07/040726090342.htm (accessed March 29, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, March 29, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins